SCHEMBL3676881

SCHEMBL3676881

COc1ccc(-c2ccc(-c3ccc(C)cc3)cc2)cc1

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.83
NPC1 O15118 3/20 0.63
RAB9A P51151 3/20 0.63
KMT2A Q03164 1/20 0.63
RELA Q04206 1/20 0.62
CA12 O43570 1/20 0.61
CA1 P00915 1/20 0.61
CA2 P00918 1/20 0.61
CA7 P43166 1/20 0.61
CA9 Q16790 1/20 0.61
CA14 Q9ULX7 1/20 0.61
ESR2 Q92731 1/20 0.61
SMN1; SMN2 Q16637 2/20 0.55
MAPT P10636 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55
TP53 P04637 1/20 0.54
MAPK1 P28482 1/20 0.54
CASP3 P42574 1/20 0.54
SENP8 Q96LD8 1/20 0.54
SENP7 Q9BQF6 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL295716 1.00 ACHE (0.83) ACHENPC1RAB9AKMT2ARELA
SCHEMBL12714843 1.00 ACHE (0.83) ACHENPC1RAB9AKMT2ARELA
Hydrazine SCHEMBL27971879 0.95 ACHE (0.75) ACHENPC1RAB9AKMT2ARELA
SCHEMBL12276818 0.93 ACHE (0.71) ACHENPC1RAB9AKMT2ARELA
SCHEMBL12334794 0.93 ACHE (0.71) ACHENPC1RAB9AKMT2ARELA
SCHEMBL12761860 0.93 ACHE (0.71) ACHENPC1RAB9AKMT2ARELA
SCHEMBL12770835 0.93 ACHE (0.71) ACHENPC1RAB9AKMT2ARELA
SCHEMBL12335539 0.93 ACHE (0.71) ACHENPC1RAB9AKMT2ARELA
SCHEMBL18708707 0.93 ACHE (0.71) ACHENPC1RAB9AKMT2ARELA
SCHEMBL14826485 0.93 ACHE (0.71) ACHENPC1RAB9AKMT2ARELA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230150919-A1 Method for Producing Mono-Cross-Coupled Aromatic Compound Having Leaving Group NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) 2023-05-18 US disclosed
US-20220216422-A1 Electroluminescent Device UDC IRELAND LTD (IE) 2022-07-07 US disclosed
US-11332670-B2 Side-chain liquid crystal polymer, liquid crystal composition, retardation film, method for producing retardation film, transfer laminate, optical member, method for producing optical member, and display device DAI NIPPON PRINTING CO., LTD. (JP) 2022-05-17 US disclosed
US-20190136134-A1 SIDE-CHAIN LIQUID CRYSTAL POLYMER, LIQUID CRYSTAL COMPOSITION, RETARDATION FILM, METHOD FOR PRODUCING RETARDATION FILM, TRANSFER LAMINATE, OPTICAL MEMBER, METHOD FOR PRODUCING OPTICAL MEMBER, AND DISPLAY DEVICE DAI NIPPON PRINTING CO., LTD. (JP) 2019-05-09 US disclosed
US-9923148-B2 Electroluminescent device UDC IRELAND LIMITED (IE) 2018-03-20 US disclosed
US-20170194568-A9 Electroluminescent Device UDC IRELAND LIMITED (IE) 2017-07-06 US disclosed
US-20130079517-A1 Electroluminescent Device BASF SE (DE) 2013-03-28 US disclosed
US-8012602-B2 Blue emitting, durable, organoelectroluminescent layers containing pyrimidine moieties; full color displays; light emission efficiency and brightness BASF SE (DE) 2011-09-06 US disclosed
US-7838089-B2 with biphenylcyclohexane-based skeleton; nematic at room temperature, improved response; paraelectric SONY CORPORATION (JP) 2010-11-23 US disclosed
US-7838089-B2 with biphenylcyclohexane-based skeleton; nematic at room temperature, improved response; paraelectric SONY CORPORATION (JP) 2010-11-23 US disclosed
US-20100240892-A1 ELECTROLUMINESCENT DEVICE SCHAEFER THOMAS 2010-09-23 US disclosed
EP-2170396-A1 DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY BioMarin IGA Limited (BS) 2010-04-07 EP disclosed
US-20090168009-A1 with biphenylcyclohexane-based skeleton; nematic at room temperature, improved response; paraelectric SONY CORPORATION (JP) 2009-07-02 US disclosed
US-20090168009-A1 with biphenylcyclohexane-based skeleton; nematic at room temperature, improved response; paraelectric SONY CORPORATION (JP) 2009-07-02 US disclosed
US-20090102373-A1 Electroluminescent device HAYOZ PASCAL 2009-04-23 US disclosed
WO-2009019504-A1 DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY SUMMIT CORPORATION PLC (GB) 2009-02-12 WO disclosed
US-20070080628-A1 Electroluminescent devices comprising 2-(p-triphenyl)-3-phenyl-pyrazine derivatives CIBA SPECIALTY CHEMICALS CORP. 2007-04-12 US disclosed
US-20070080628-A1 Electroluminescent devices comprising 2-(p-triphenyl)-3-phenyl-pyrazine derivatives CIBA SPECIALTY CHEMICALS CORP. 2007-04-12 US disclosed
EP-1687856-B1 ELECTROLUMINESCENT DEVICES COMPRISING 2-(P-TRIPHENYL)-3-PHENYL-PYRAZINE DERIVATIVES CIBA SC HOLDING AG (CH) 2007-02-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150919-A1 Method for Producing Mono-Cross-Coupled Aromatic Compound Having Leaving Group DDC, PAH, ATIC ACHE 2454/4885NPC1 2885/4885RAB9A 2875/4885
US-20220216422-A1 Electroluminescent Device PNPO, ODC1, AXL ACHE 183/4885NPC1 4737/4885RAB9A 2872/4885
US-20090102373-A1 Electroluminescent device TAAR5, TYR, TRPC5 ACHE 219/4885NPC1 4847/4885RAB9A 3537/4885
US-20170194568-A9 Electroluminescent Device DPYD, PNPO, TYMP ACHE 325/4885NPC1 4733/4885RAB9A 3141/4885
US-20130079517-A1 Electroluminescent Device DPYD, PNPO, TYMP ACHE 325/4885NPC1 4733/4885RAB9A 3141/4885
US-20100240892-A1 ELECTROLUMINESCENT DEVICE PNPO, ODC1, AXL ACHE 183/4885NPC1 4737/4885RAB9A 2872/4885
US-20070080628-A1 Electroluminescent devices comprising 2-(p-triphenyl)-3-phenyl-pyrazine derivatives C1S, TYR, C5 ACHE 1325/4885NPC1 4715/4885RAB9A 3466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.